VNDA
VandaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull case is that Q1 contained several real positives at once: Fanapt growth was strong, NEREUS launched, BYSANTI already has FDA approval, full-year revenue guidance was raised, and imsidolimab still offers a meaningful December 2026 regulatory shot on goal [#8-K-2026-05-06].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.7.
What can break
Cash, cash equivalents and marketable securities were $202.3 million at March 31, 2026 after a $61.5 million quarterly decline, including a $10 million NEREUS-related milestone payment, so runway and spend discipline remain important [#8-K-2026-05-06].
Momentum
13
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.90 · Bull $10.50 · Bear $4.25
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $14.13
Why
Momentum13 · Δ7d 0.0
Value41 · Δ7d +0.0
Sentiment75 · Δ7d +11.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
13
26% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-9.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
75
34% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+10.0
Why this grade
Composite grade D. Momentum 12.7 / Value 41.1 / Sentiment 75.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$319.92M
Beta
0.63
Shares Out
60.14M
P/E (TTM) · Derived
-1.4
P/S (TTM)
2.19
P/FCF (TTM) · Derived
-2.48
Rev YoY
+3.4%
EPS YoY
+62.1%
Gross Margin
+89.9%
Op Margin
-57.1%
Net Debt
-$251.33M
Current Ratio
2.16
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology